Lantern Pharma INC Form 4 insider transactions

NASDAQ
Aaron G.L. Fletcher, a director of Lantern Pharma, and related BIOS funds, reported the sale of common stock between February 27 and February 29, 2024.
NASDAQ
Leslie Kreis, a director and 10% owner of Lantern Pharma, along with related entities including Bios Funds and BP Directors, sold shares of LTRN common stock in a series of transactions from February 27-29, 2024.